author-photo

Nathan Standifer

AstraZeneca

11

Papers

34

Citations

Citation Trend

Filter By

Papers (6) Sort By

Journal Conference Others

Resistance to durvalumab and durvalumab plus tremelimumab is associated with functional STK11 mutations in non-small-cell lung cancer patients and is reversed by STAT3 knockdown.

2021 Cancer Discovery
Show All
- Source
- Cite
- Save
Citations (2)
Exposure-response (E-R) efficacy and safety (E-S) analyses of tremelimumab as monotherapy or in combination with durvalumab in patients (pts) with unresectable hepatocellular carcinoma (uHCC).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Best practices for optimization and validation of flow cytometry-based receptor occupancy assays.

2020 Cytometry Part B-clinical Cytometry
Show All
- Source
- Cite
- Save
Citations (3)
275 Translational endpoints associated with STK11 mutations in patients with non-squamous NSCLC

2020 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
274 Tumoral and peripheral immunophenotype of refractory vs relapse to PD-(L)1 blockade in patients with advanced non-small cell lung cancer

2020 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Abstract B55: Exploratory biomarker analyses of tumor and peripheral blood samples from the phase I durvalumab plus gefitinib trial in EGFR-mutated NSCLC

2020 Cancer immunology research
Show All
- Source
- Cite
- Save
Citations (0)